Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma

Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma

Abstract The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients with PDAC (42% with metastatic disease) at MD Anderson Cancer Center. Overall survival (OS) analysis demonstrated that KRAS...

Full description

Bibliographic Details
Main Authors: Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, Kawther Abdilleh, Mark Knafl, Paul Edelkamp, Kristin Alfaro-Munoz, Ray Chacko, Jennifer Peterson, Brandon G. Smaglo, Robert A. Wolff, Shubham Pant, Michael S. Lee, Jason Willis, Michael Overman, Sudheer Doss, Lynn Matrisian, Mark W. Hurd, Rebecca Snyder, Matthew H. G. Katz, Huamin Wang, Anirban Maitra, John Paul Shen, Dan Zhao
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-024-00505-0

Internet

https://doi.org/10.1038/s41698-024-00505-0

Similar Items